Huperzine A in SCI

Harvard Medical School researchers have shown that the plant-derived small molecule huperzine A can reduce neuropathic pain in rats with spinal cord injury.¹ Insero Health Inc. has licensed IP from Harvard covering the use of huperzine A to treat epilepsy and neuropathic pain and plans to report Phase Ib data this year in treatment-resistant epilepsy.

Neuropathic pain is one of the most frequent complications associated with spinal cord injury (SCI), occurring in at least 40% of patients.² Because there are multiple pathways and mechanisms that underlie pain in SCI,³ the Harvard team hypothesized that a single compound with effects on those pathways might have a better chance of success than a compound against a single target...